Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC Ltd : World’s leading Event Organizer

Conference Series LLC Ltd Conferences gaining more Readers and Visitors

Conference Series LLC Ltd Web Metrics at a Glance

  • 3000+ Global Events
  • 100 Million+ Visitors
  • 75000+ Unique visitors per conference
  • 100000+ Page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Recommended Global Pharma Marketing & Industry Conferences

Europe & UK
Asia Pacific & Middle East

Pharma Formulations 2020

About Us

After the successful completion of the 16th International Conference on Pharmaceutical Formulations & Drug Delivery, Conference Series with great pride and honour announcing its 17th International Conference on Pharmaceutical Formulations& Drug Delivery October 30-31, 2020 at Vancouver, Canada This Pharma Formulations 2020 includes a wide range of Keynote presentations, plenary talks, Symposia, Workshops, Exhibitions, Poster presentations and Career development programs

Why to Attend???

Pharma Formulations 2020 Conference is a multidisciplinary program with broad participation with members from around the globe focused on learning about formulations and drug delivery and its advances. This is your best opportunity to reach the largest assemblage of participants from Pharma research community that is from academia, drug delivery entities, medical groups, related associations, societies and also from government agencies, pharmaceutical, biomedical and medical device industries.

Pharma Formulations 2020 will discuss various disciplines involved in the drug formulation procedures and drug delivery technologies; it will educate health care researchers about design, operation, organizing, research computing, regulatory aspects and reporting of formulations. This conference conduct presentations, distribute information, meet with current and potential scientists, make a splash with new pharma research developments, and receive name recognition at this 2-days event. World renowned speakers and the most recent techniques, developments, the newest updates in formulations and drug delivery are hallmarks of this conference.

Who Should Attend and Who You’ll Meet

Directors/Senior Directors/Executive Directors and Vice Presidents/Senior Vice Presidents/Executive Vice Presidents and Heads/Leaders/Partners of

•           CROs and CMOs

•           Pharma Research Sites

•           Pharma/Biotech and Medical Device industries

•           Hospitals, Associations

Medical Directors, Principal Investigators, Methodologists, and other Pharmaceutical research professionals along with Academicians: University Faculties like Directors, Senior Professors/Assistant Professors/ Associate Professor, Research Scholars, scientists who are related to pharmaceutical research.

Sessions & Tracks

Track 1: Pharmaceutical Formulations: Academic and Industry Perspective

Increasingly, medicines research is moving from ‘big Pharma’ to small biotech companies and start-ups. To succeed in this new environment, scientific skills are not enough employers and financiers also need to be confident that the people they are working with possess the entrepreneurial skills to grow and sustain a business effectively. Pharmaceutical formulation development enables development of robust and compliant formulations and resolve difficult challenges encountered during preclinical and clinical development.

Track 2: Pharmaceutical Research and Development

For developing a new medicine it will take nearly 10-15 years and on average and costs an average of $2.6 billion. In discovery procedure comprises the initial stages of research, which are intended to recognize an investigational drug and perform primary tests in the lab. This first stage of the process takes   three to six years. By the end, investigators hope to identify a capable drug aspirant to further study in the lab and in animal models, and then in people. These developments offer great ability, but also add complexity to the R&D process. In order to ensure the safety and efficacy of personalized therapies that are used along with diagnostics, clinical trial protocols must be improved and increased.

Track 3: Drug Designing and Development

Researchers discover new drugs through insights into a disease process that allow researchers to design a product to stop or reverse the effects of the disease. Once researchers identify a promising compound for development, they conduct experiments to gather information on how it is absorbed, distributed, metabolized, and excreted, best dosage, Side effects, how it interacts with other drugs and treatments and its effectiveness as compared with similar drugs.

Bringing one new drug to the public typically costs a pharmaceutical or biotechnology company on average more than $1 billion and takes an average of 10 to 15 years. Each drug undergoes a stringent process of discovery, development, approval and finally, public use.

Track 4: Pharmaceutical Excipients Development

Pharmaceutical excipients have a vital role in formulations. Choosing of excipients is an important in Drug Development. Excipients will have the ideal pharmacokinetic properties. Existing regulations and guidelines indicate that new (novel) excipients should be treated as new chemical entities with full toxicological evaluation. Excipients are now known to have defined functional roles in pharmaceutical dosage forms. Excipients can influence both safety and efficacy outcomes of the drugs.  Excipients play a vital role in Drug delivery systems. Excipients  are  designed  to  be biologically  inactive,  removing  this  barrier  could  provide  a potentially immediate, low-risk solution to the current shortage of new drug formulations.

The global excipient market size is expected to grow to USD 6.9 billion by 2025, a compound annual growth rate (CAGR) of 6.02% from 2017 to 2025.

Track 5: Novel Drug Formulation Procedures

Novel Drug Formulation Procedure is an innovative drug development method which focuses to employ the novel methodologies developed by pharmaceutical industry for a specific intentional use in pharmaceutical Research and development.

Novel drug procedure with unique mechanism offers a much needed treatment option to improve the condition. Bioavailability of the API may be exchanged off when attempting to modify entry of the API due to parts, for instance, gastric upkeep or bypassing the absorptive "window" of the duodenum.

Track 6: Pharmaceutical Nanotechnology: Challenges and Opportunities

Pharmaceutical nanotechnology is most innovative field in the pharmaceutical industry. Nano technology is dealing with new emerging technologies. Application of nanotechnology in imaging, diagnostics and therapeutics is considered as an important factor. The drug delivery system positively impacts the rate of absorption, distribution, metabolism, and excretion of the drug or other related chemical substances in the body. Within regulatory boundaries thermodynamics and nanotechnology are considered to be evolving tools to provide new and integrated knowledge for the production of new medicines.

Nanotechnology speaks to a stage for creating progressive changes and enhancements to a wide range of parts of pharmaceutical assembling. Pharmaceutical nanotechnology has provided fine-tuned diagnosis and focused treatment of disease at a molecular level. Nano technology is having an utmost importance in Gene therapy.

Track 7: Pharmaceutical Formulations: Types and Novelties

Pharmaceutical formulations vary on the route of administration. Eternal formulations prolong the action of duration of drug. Eternal formulation includes tablet, capsule and sustained release dosage forms. Parenteral formulation impacts both the safety and efficacy of drug.

The effect of the dosage form depends on the route of administration. A low medication load may cause homogeneity issues. A high medication load may posture stream issues or require extensive containers if the compound has a low mass thickness.

Track 8: Bioavailability and Bioequivalence Studies

Bioavailability and Bioequivalence are designed to FDA evaluation of the safety and effectiveness of a product .BA for a given formulation provides an estimate of the relative fraction of the orally 94 administered doses that is absorbed into the systemic circulation. Bioavailability and Bioequivalence mainly focus on the release of a drug substance from a drug. Several in-vitro and in-vivo methods are used to measure the bioavailability of the drugs. For BA and BE studies a single-dose, fasting study be performed. BA studies provide other useful pharmacokinetic information related to distribution, elimination, the effects of nutrients on absorption of the drug, dose proportionality, linearity in pharmacokinetics of the active moieties and, where appropriate, inactive moieties.

Track 9: Pharmaceutical Analysis Methods

For the administration of drugs various chemical and instrumental methods were developed at regular intervals which are involved in the estimation of drugs. Analytical instrumentation and methods play an important role. Different analytical techniques and electrochemical methods like Chromatographic techniques, HPLCGas chromatography.  From the stages of drug development to marketing and post marketing, analytical techniques play a great role in understanding the physical and chemical stability of the drug, identification of impurities. Analytical techniques are mainly used to determine the safety and efficacy of the drug

Track 10: Challenges in Drug Administration

Medication are used to prevent and illness. Depending upon their site of action and safety and efficacy of drug drugs can be administered through a variety like oral, parenteral, TransdermalIntradermal etc.. While administering a drug we have to consider the possible side effects and dangerous reactions also. The Dosage of the drug has to be carefully determined. In US, it has been estimated that 80 per cent of active ingredients and 40 per cent of the final drug products are imported. Medicine slant and bolster significance have been surveyed by taking a gander at the self-association of no less than two drugs open under various trial conditions, including choice procedure, dynamic extent fortress timetables, and chain stronghold logbooks.

Track 11: Drug Delivery Technologies

Particle Sciences has a great deal of successful experience in the development of successful delivery systems for many types of APIs and sites of action. Drug delivery technologies enhance drug absorption, efficacy, and patient experience. Enhancing the drug delivery technology of final pharmaceutical formulation can increase its commercial success. Drug delivery systems have been used in delaying drug clearance processes. Drug delivery approaches have their advantages and limitations.  Drug delivery approaches include solubilizationpermeability enhancement, modified release (MR)

The global drug delivery technology market is projected to reach USD 1,669.40 Billion by 2021 from USD 1,179.20 Billion in 2016, at a CAGR of 7.2% during the forecast period. The North American drug delivery technologies market is projected to reach USD 758.7 Billion by 2021 from USD 520.0 Billion in 2016, at a CAGR of 6.5% during the forecast period.

Track 12: Novel Drug Delivery Systems

Drug delivery systems control the pharmacokinetics, pharmacodynamics, non-specific toxicity, immunogenicity and efficacy of drugs. NDDS is a combination of advance technique and new dosage forms which are far better than conventional dosage forms. Novel drug delivery system classified in to different types based on the diffusion types. Drug Delivery Carriers show great promise as drug delivery systems. Drug delivery may be either active or passive process.  These are designed to target the site specific region, in order to achieve desired therapeutic effect, thereby reducing the side or toxic effects. NTTD Increases the efficacy of the drug and decrease side effects.

The global market for drug delivery systems is expected to rise at a compound annual growth rate (CAGR) of 5% and reach nearly $175.6 billion by 2021.

Track 13: Wearable Drug Delivery

These are changing the world of drug delivery and preventing the patients from continuous bulk ambulatory devices. Wearable drug delivery device delivers insulin to the wearer.  These are developed for dosing a range of drugs such as hormones, analgesics, anti-hypertensives. Large doses 5ml to 50 ml can be comfortably be self-administered by the patient at home by using the Wearable Drug Delivery devices. The life cycle of the product can also be increases. Wearable technology speeds the Formulation and development.

The annual growth rate is expected to reach USD $824 bn by 2025. The size of the market opportunity for LVI devices alone has been estimated at $8.1 billion by 2025, with over 50% of this driven by devices to deliver drugs for cancer and related conditions.

Track 14: Transdermal & Intradermal Drug Delivery Systems

Transdermal Drug Delivery system is an integral part of novel drug delivery system. Drugs having long pharmacokinetic half-lives are considered to be Unsuitable for transdermal application. By the increased number of marketing authorization applications together with recent scientific developments for transdermal patches, the need for clear guidance on specific requirements for this dosage form increased.

The emergence of technological innovations in transdermal patches is expected to provide the market with lucrative growth opportunities over the coming years. Transdermal Drug Delivery system was valued at $32,516 million in 2016, and is estimated to reach $61,689 million by 2023, growing at a CAGR of 9.5%.

Track 15: Drug Delivery approaches for Parenterals

Parenteral Drug Delivery has been developed alternative to the normal route of administration. The success depends on clinical as well as on patient compliance. This route is mainly used for the drugs having poor aqueous solubility and this route improves the patient compliance and decreases the systemic availability. Chitosan is used as micro particlesliposomes, granules, and gels for oral and parenteral drug delivery. Parenteral administration route is the most common for delivery of active drug substances with a narrow therapeutic index. This route of administration may cause less cardiac attacks and respiratory attacks. Parenteral delivery still remains the major mode of administration for protein and peptide therapeutics

Track 16: Drug Delivery Devices: Approaches and Manufacturing

 A new class of drug delivery device which can inject doses far larger than today’s syringes or auto injectors has developed i.e., Bolus Injectors having the capability to deliver more than 1 ml of a drug subcutaneously in a simple, reliable, and inexpensive manner. In the last 12 years, drugs have been delivered using self-regulated and Nano-technology systems. The manufacturers need to consider clinical guidelines and regulatory requirements governing combination products also differ from both pharmaceuticals and medical devices.

To change that perception, the FDA last year announced $40 million to a new Medical Device Innovation Consortium (MDIC) charged with simplifying the process of designing and testing new technologies. With input from industry, government, and other nonprofit organizations, public-private MDIC will prioritize the regulatory science needs of the medical device community and fund projects to streamline the process.

Track 17: Pharmaceutical IPR and Regulatory Affairs

Development of a new pharmaceutical product requires at least 15 years because of changes in the regulatory. Regulatory Affairs Department acts as the interface between the pharmaceutical company and the regulatory agencies across the world. Regulatory authorities act a vital role for approval of generics.

Regulatory Affairs contributes essentially to the overall success of drug development, both at early pre-marketing stages and at all times post-marketing. Regulatory Affairs professionals can play a key role in guiding drug development strategy in an increasingly global environment.

North America and Europe contribute about 57.0% of global pharmaceutical sales. The global regulatory affairs outsourcing market size was valued at USD 4.53 billion in 2016 and is expected to grow at a CAGR of 11.9% over the forecast period.

Market Analysis

Pharmaceutical Formulations and Drug Delivery Conference will examine compelling definition and conveyance advances for upgrading solvency and medication conveyance. Pharma Formulations 2020 expects to total driving specialists from around the globe who will talk about on definition and conveyance, and show how they are forming ineffectively dissolvable medications into logically solid, tolerant driven details, and lessening their item improvement courses of events.

For what reason to visit???

Chances to meet with profoundly qualified companions to approve methodologies. Driving industry speakers and illuminators. Figure out how pharma Formulations 2020 can assist your organization with its items and administrations. Exploit the broadness and profundity of substance/issue which supportive. Sessions are intended to furnish participants with the most recent bits of knowledge.

The Competition Bureau advances and secures focused markets over the whole economy. The Bureau isn't liable for implementing the common and criminal arrangements of the Competition Act, it is additionally answerable for upholding for more noteworthy dependence on advertise powers to convey the advantages of rivalry to Canadians.

Canada's wellbeing framework is a zone where rivalry is frequently seen as assuming a restricted job. Actually focused markets are answerable for conveying huge numbers of the items and administrations on which our wellbeing framework depends. Given their significance to the welfare of Canadians and in light of the fact that this is a huge market — at roughly 10% of GDP, wellbeing related markets have been a key requirement and backing need for the Bureau for quite a while.

The Bureau's wellbeing related backing action has concentrated on pharmaceuticals. This mirrors the job of pharmaceuticals in regarding patients and their significance as a wellspring of social insurance costs — at $17.8 billion out of 2006, they are the second biggest wellspring of medicinal services costs. The Bureau has explicitly concentrated on endorsed nonexclusive pharmaceuticals. Generics assume a significant job in keeping wellbeing costs somewhere around giving challenge to mark drugs when they lose patent assurance.

A few examinations have seen solution generics as moderately more costly in Canada than in different nations. The examinations incited the Bureau to direct the nonexclusive medication division concentrate to look at the conventional medication advertise and recognize zones where changes in the market system may verify more prominent advantages through challenge.

In directing the investigation, the Bureau depended on openly accessible data, information bought from information suppliers, and data intentionally gave by division members. In July 2007, a fundamental draft of the examination was flowed to key intrigue bunches for certainty checking and to furnish them with a chance to offer extra data.

Key discoveries in the investigation incorporate the accompanying:

• Generic drugs are provided through a one of a kind and complex structure. Doctors endorse medicine to be taken by patients. In filling the solution, drug stores can supply any brand name or conventional medication item recorded on models (or medication plan item records) as tradable for the endorsed prescription. Medications are paid for by tranquilize protection designs or out of pocket by buyers. Government and private medication plans give inclusion to around 98% all things considered. Drug stores are typically followed through on the receipt cost.

• Generic fabricating has gotten progressively aggressive in the course of recent years. Apparently solid challenge exists in the inventory of numerous conventional medications in Canada. The finish of patent assurance for a medication would now be able to prompt stockpile inside a brief time of numerous exchangeable conventional items.

•  In most areas, a significant manner by which makers contend to have their item supplied by drug stores is by offering them discounts off receipt costs. Discounts give motivating force to drug stores to choose a specific producer's item. It has not been conceivable to get definite proof with respect to the size of these refunds. Open sources and data gave by parties met to this investigation gauge these to be 40 percent of the value the drug store is invoiced. Discounts are at present disallowed in two territories, Ontario and Quebec. In any case, enactment received in Ontario in 2006, and viable in Quebec, enables conventional medication producers to give proficient stipends to drug stores.

• Competition by conventional makers to offer lower costs through refunds isn't reflected in costs paid by either open or private plans, or out of pocket. Or maybe, as of not long ago, costs paid for conventional medications the nation over would in general mirror the greatest nonexclusive medication costs permitted under Ontario's medication plan. This changed in 2006 when Ontario scaled down the most extreme it would pay for conventional medications to half of the brand name item cost. These lower costs are not paid by private medication designs in Ontario, or medication designs in different regions, in spite of the fact that this estimating discipline is expected to be received in Quebec in 2008.

• Plans join different approaches, for example, greatest conventional costs thus called "most supported country" provisions, to decrease their nonexclusive medication costs. In any case, these arrangements give constrained motivation to producers to contend by offering aggressive conventional costs to the plans.

An administrative and market system where motivating forces to supply medicate designs all the more intently mirror the basic market elements could give huge advantages to sedate plans, and thusly to safety net providers, bosses and Canadians.

The Competition Bureau will proceed with its work in the nonexclusive medication area by analyzing potential choices for getting the advantages from rivalry and the obstacles to their appropriation. Measures for achieving this objective may incorporate, for instance:

• providing producers with motivations to contend to be recorded on plan models;

• using focused offering procedures to decide the items that can be apportioned by drug stores;

• monitoring of the net value paid by drug stores for conventional medications to guarantee the value followed through on by plans reflects focused costs; and,

• an expanded job for private plans in getting lower costs for their clients.

To Collaborate Scientific Professionals around the World

Conference Date October 30-31, 2020

For Sponsors & Exhibitors

[email protected]

Speaker Opportunity

Past Conference Report

Supported By

All accepted abstracts will be published in respective Conference Series LLC LTD International Journals.

Abstracts will be provided with Digital Object Identifier by